Bienvenue dans notre banque interrogeable de ressources et de documentation sur l’approvisionnement plus sécuritaire et autres sujets connexes.
Short visual summary of Blood Ties' "Don't Be An A**hole" best practices report
Ressources
Infographic | 2018
Clinical guidance, Wrap-around services, Equity, About prescribers, About PWUD, Social services, Barriers and enablers, Indigenous, Small/medium cities, Stigma
Outlines key themes found among people who use drugs about their experiences with various health and social service agencies and providers in Whitehorse
Report | 2018
Clinical guidance, Wrap-around services, Equity, About prescribers, About PWUD, Social services, Barriers and enablers, Indigenous, Small/medium cities, Stigma
Guidelines | 2020
Clinical guidance, About pharmacists, About prescribers
Pharmacists Guidelines for risk mitigation in BC from Vancouver Coastal Health
Guidelines | 2020
Clinical guidance, Harm reduction, Policy/Regulatory, Safer supply, About pharmacists, Stimulants, Substitution/OAT, Injecting drugs
Prescriber Guidelines for risk mitigation in BC from Vancouver Coastal Health
Guidelines | 2020
Clinical guidance, Harm reduction, Policy/Regulatory, Safer supply, About prescribers, Stimulants, Substitution/OAT, Injecting drugs
Very little is known about the value of UDS, the optimum screening frequency in general, or its specific use for buprenorphine treatment in primary care.
Original research | 2021
Clinical guidance, About prescribers, Outcomes, Substitution/OAT, Diversion
Guidelines | 2021
Clinical guidance, About prescribers, Chronic pain
Provide clinical guidance to ensure the uninterrupted access to OAT medications for patients during the COVID-19 pandemic.
Guidelines | 2020
Clinical guidance, Harm reduction, About pharmacists, About prescribers
Commentary | 2021
Clinical guidance, Harm reduction, Hesitancy of prescribers , Safer supply, About pharmacists
Describes a 3-day induction protocol for injectable hydromorphone (HDM) and diacetylmorphine (DAM) used in 3 Canadian studies and examine rates of opioid-related overdose and somnolence during this in
Original research | 2019
Clinical guidance, Evidence base, Harm reduction, Safer supply, About prescribers, Outcomes, Substitution/OAT, Injecting drugs
To raise awareness of alternative techniques that can facilitate buprenorphine-naloxone treatment for opioid use disorder.
Original research | 2020
Clinical guidance, Harm reduction, About prescribers, Substitution/OAT
Shared decision-making (SDM) is an approach to clinical decision-making that includes patients' values and preferences during health-related decisions.
Scoping review | 2021
Clinical guidance, About prescribers, About PWUD
We conducted a scoping review of feasibility studies reporting on preferred SCS design characteristics, staffing models and ancillary services.
Scoping review | 2021
Overdose, Clinical guidance, About prescribers, About PWUD, Illegal drugs, SCS/OPS
This Rapid Response report aims to review the effectiveness of the use of telehealth-delivered OAT compared to standard OAT.
Lit review | 2018
Clinical guidance, Evidence base, Policy/Regulatory, Safer supply, About prescribers
Users of poppy seed tea (PST) can consume several hundred morphine milligram equivalents per day, and opioid dependence from PST use can develop.
Original research | 2021
Withdrawal, Clinical guidance, Hesitancy of prescribers , About prescribers, Outcomes, Chronic pain, Substitution/OAT, Stigma
Despite a current lack of direct evidence, this document has been created to urgently combat overdose deaths. It is informed by existing research and based out of expert opinion.
Guidelines | 2020
Mortality, Clinical guidance, Harm reduction, Safer supply, About prescribers, Transitions in care/treatment, Injecting drugs, Diversion
Quebec safe supply clinical guidance for prescribers
Guidelines | 2020
Overdose, Clinical guidance, Harm reduction, Safer supply, About prescribers, Stimulants, Substitution/OAT, Transitions in care/treatment, Injecting drugs
Guide or handbook | 2020
Clinical guidance, Harm reduction, Illegal drugs, Injecting drugs
Slide deck | 2021
Clinical guidance, About prescribers, Small/medium cities
FBT is indicated for the management of breakthrough pain (a transient flare of pain on a background of chronic pain otherwise controlled by treatment with opioids) in patients with cancer who are alre
Original research | 2008
Clinical guidance, About prescribers, Chronic pain
